uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:QURE
Previous Symbol
CUSIPN/A
Phone31-20-566-7394
Debt
Debt-to-Equity Ratio0.05
Current Ratio7.56
Quick Ratio7.56
Price-To-Earnings
Trailing P/E Ratio-9.57
Forward P/E Ratio-10.95
P/E GrowthN/A
Sales & Book Value
Annual Sales$13.11 million
Price / Sales80.02
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.90 per share
Price / Book9.70
Profitability
EPS (Most Recent Fiscal Year)($2.94)
Net Income$-79,260,000.00
Net Margins-725.04%
Return on Equity-58.49%
Return on Assets-35.86%
Miscellaneous
Employees202
Outstanding Shares37,280,000
Market Cap$1.05 billion
OptionableOptionable
Uniqure (NASDAQ:QURE) Frequently Asked Questions
What is Uniqure's stock symbol?
Uniqure trades on the NASDAQ under the ticker symbol "QURE."
How were Uniqure's earnings last quarter?
Uniqure NV (NASDAQ:QURE) released its quarterly earnings results on Tuesday, November, 6th. The biotechnology company reported ($0.59) earnings per share for the quarter, beating analysts' consensus estimates of ($0.62) by $0.03. The biotechnology company had revenue of $3.15 million for the quarter, compared to analyst estimates of $3.37 million. Uniqure had a negative net margin of 725.04% and a negative return on equity of 58.49%. View Uniqure's Earnings History.
When is Uniqure's next earnings date?
What price target have analysts set for QURE?
9 brokers have issued 1 year price targets for Uniqure's shares. Their predictions range from $30.00 to $76.00. On average, they expect Uniqure's stock price to reach $58.50 in the next year. This suggests a possible upside of 107.9% from the stock's current price. View Analyst Price Targets for Uniqure.
What is the consensus analysts' recommendation for Uniqure?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Uniqure in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Uniqure.
What are Wall Street analysts saying about Uniqure stock?
Here are some recent quotes from research analysts about Uniqure stock:
- 1. HC Wainwright analysts commented, "Our $60 price target vs. prior $48, is based on a 13-year DCF analysis that incorporates rNPV of two clinical-stage pipeline products AMT-061 and AMT-130. For AMT-061, we assume a 70% POS driven by the compelling clinical update, refer to our November 15, 2018 note for details, vs. 65% POS previously and anticipate commercial launch during 2H-2021, with a lower NAB-based exclusion of 5% vs. prior 10%, and model risk-adjusted peak sales of roughly $1.14B (vs. $981M previously), during 2028. We assume a launch price of $850K (vs." (11/26/2018)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and are raising our 12- month price target to $65 from $58. This morning, uniQure announced initial top- line data from the Phase 2b dose-confirmation study of AMT-061 for the treatment of severe hemophilia B. Data from three patients show a mean factor IX (FIX) level of 31% six weeks post-administration. Importantly, there were no bleeding events, use of factor infusions, or required immunosuppression. The data met uniQure’s projected goals in FIX activity levels, which we believe supports moving forward with dosing in the Phase 3 HOPE-B trial. We expect to hear additional details at the company November 19." (11/15/2018)
- 3. Chardan Capital analysts commented, "We note organ-specific promoters will help mitigate toxicity issues associated with off-target expression of transgenes. In addition, better promoters means potentially lower dosage of vector genomes will be required to achieve therapeutic levels of therapeutic protein levels." (10/18/2018)
- 4. According to Zacks Investment Research, "UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. " (10/17/2018)
Has Uniqure been receiving favorable news coverage?
News stories about QURE stock have been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Uniqure earned a news impact score of 1.2 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the next few days.
Are investors shorting Uniqure?
Uniqure saw a increase in short interest in the month of November. As of November 30th, there was short interest totalling 1,663,956 shares, an increase of 63.5% from the November 15th total of 1,017,668 shares. Based on an average daily volume of 440,798 shares, the short-interest ratio is presently 3.8 days. Approximately 7.7% of the company's stock are short sold. View Uniqure's Current Options Chain.
Who are some of Uniqure's key competitors?
Some companies that are related to Uniqure include TESARO (TSRO), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO), Array Biopharma (ARRY), FibroGen (FGEN), Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Emergent Biosolutions (EBS), Agios Pharmaceuticals (AGIO), Evotec (EVTCY), Ligand Pharmaceuticals (LGND), Akcea Therapeutics (AKCA), Ascendis Pharma A/S (ASND), Allakos (ALLK) and Endo International (ENDP).
Who are Uniqure's key executives?
Uniqure's management team includes the folowing people:
- Mr. Matthew Craig Kapusta, CEO, CFO & Exec. Director (Age 46)
- Dr. Sander Van Deventer M.D., Ph.D., Co-founder, Chief Scientific Officer & Gen. Mang. of Amsterdam (Age 64)
- Mr. Jonathan Garen, Chief Bus. Officer (Age 52)
- Prof. Hugo Katus, Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
- Dr. Scott T. McMillan, Chief Operating Officer (Age 59)
Who are Uniqure's major shareholders?
Uniqure's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (9.89%), Redmile Group LLC (4.40%), Federated Investors Inc. PA (4.20%), Perceptive Advisors LLC (2.61%), FIL Ltd (2.23%) and Macquarie Group Ltd. (1.60%). Company insiders that own Uniqure stock include Christian Klemt, David Schaffer, Deventer Sander Van, Harald Petry, Maria E Cantor, Matthew C Kapusta, Philip Astley-Sparke and Steven Zelenkofske. View Institutional Ownership Trends for Uniqure.
Which institutional investors are selling Uniqure stock?
QURE stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Morgan Stanley, FIL Ltd, Royce & Associates LP, First Manhattan Co., FMR LLC, Virtus ETF Advisers LLC and Victory Capital Management Inc.. Company insiders that have sold Uniqure company stock in the last year include Christian Klemt, David Schaffer, Deventer Sander Van, Maria E Cantor, Matthew C Kapusta, Philip Astley-Sparke and Steven Zelenkofske. View Insider Buying and Selling for Uniqure.
Which institutional investors are buying Uniqure stock?
QURE stock was bought by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Henry James International Management Inc., Franklin Resources Inc., Bluefin Trading LLC, Sphera Funds Management LTD., BlackRock Inc., Redmile Group LLC and Virtu Financial LLC. View Insider Buying and Selling for Uniqure.
How do I buy shares of Uniqure?
Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Uniqure's stock price today?
One share of QURE stock can currently be purchased for approximately $28.14.
How big of a company is Uniqure?
Uniqure has a market capitalization of $1.05 billion and generates $13.11 million in revenue each year. The biotechnology company earns $-79,260,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis. Uniqure employs 202 workers across the globe.
What is Uniqure's official website?
How can I contact Uniqure?
Uniqure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at 31-20-566-7394 or via email at [email protected]
MarketBeat Community Rating for Uniqure (NASDAQ QURE)
MarketBeat's community ratings are surveys of what our community members think about Uniqure and other stocks. Vote "Outperform" if you believe QURE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QURE will underperform the S&P 500 over the long term. You may vote once every thirty days.
